Fidelity Disruptive Medicine ETF (NASDAQ:FMED – Get Free Report) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 6,541 shares, a growth of 495.7% from the August 15th total of 1,098 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 7,438 shares, the days-to-cover ratio is presently 0.9 days.
Fidelity Disruptive Medicine ETF Stock Up 0.6%
Shares of Fidelity Disruptive Medicine ETF stock traded up $0.20 on Friday, reaching $31.04. The company’s stock had a trading volume of 485 shares, compared to its average volume of 10,668. The company has a market capitalization of $49.66 million, a P/E ratio of 41.33 and a beta of 0.77. The stock has a 50-day moving average price of $30.14 and a 200-day moving average price of $27.01. Fidelity Disruptive Medicine ETF has a 52-week low of $23.48 and a 52-week high of $32.89.
Hedge Funds Weigh In On Fidelity Disruptive Medicine ETF
A number of large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in shares of Fidelity Disruptive Medicine ETF during the fourth quarter worth about $228,000. Vise Technologies Inc. purchased a new position in Fidelity Disruptive Medicine ETF in the 4th quarter valued at about $234,000. Citadel Advisors LLC purchased a new position in Fidelity Disruptive Medicine ETF in the 2nd quarter valued at about $282,000. Finally, Jane Street Group LLC boosted its holdings in Fidelity Disruptive Medicine ETF by 0.8% in the 1st quarter. Jane Street Group LLC now owns 66,382 shares of the company’s stock worth $1,567,000 after buying an additional 499 shares during the last quarter.
About Fidelity Disruptive Medicine ETF
The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.
Featured Stories
- Five stocks we like better than Fidelity Disruptive Medicine ETF
- TSMC Revenue Jumps 53% in August, Signaling Strong AI Chip Demand
- This AI ETF Is Missing the Biggest AI Winners
- Could Snowflake’s Big Quarter Be a Sign of More to Come?
- Microsoft’s Azure Reporting Shift Adds Clarity, But the Bull Case Came First
Receive News & Ratings for Fidelity Disruptive Medicine ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fidelity Disruptive Medicine ETF and related companies with MarketBeat.com's FREE daily email newsletter.
